INTRODUCTION
In recent years, because of emerging technologies and changing diagnostic and treatment patterns, cancer-related expenditures have risen and are expected to rise faster than those in any other area of health care. 1, 2 The rising economic burden of cancer care on patients has been acknowledged by the American Society of Clinical Oncology, which recommended in its guidance statement on the cost of cancer care that patient-physician discussion regarding the cost of care be recognized as an important component of high-quality care and that resources be developed to educate patients about the costs of treatment and guide them in choosing treatment options. 3 On the other hand, a recent study found that between 1987 and the period of 2001 to 2005, the share of cancer costs financed by private insurance rose from 42% to 50%, whereas the outof-pocket share fell from 17% to 8%, suggesting that out-of-pocket burdens of cancer treatment are declining. 4 Thus, whether and to what extent the rising costs of cancer treatment are leading to high out-ofpocket burdens for patients with cancer are empirical questions.
Many previous studies have focused on lifetime or annual costs of cancer. [5] [6] [7] [8] [9] Our focus instead is on out-of-pocket burdens. High out-of-pocket burdens can reduce access to care and may affect treatment choice. Recent studies have shown that cancer survivors are more likely to delay or forgo medical treatment compared with those without cancer. 10, 11 Furthermore, in a recent survey, 84% of oncologists reported that patients' out-of-pocket spending influenced treatment recommendations.
12 Because of differences in benefit generosity, utilization and
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
burdens may vary significantly by type of insurance. 13, 14 Most nonelderly families have employer-sponsored insurance. In 2002 and 2003, 69% of nonelderly families had access to employer coverage, and 96% of these families had private health insurance. 15 Thus, loss of employment may lead to loss of health insurance coverage. Studies have shown that cancer-related needs can lead to loss of employment and income. [16] [17] [18] [19] The key features that distinguish our study are that first, we examined health care burdens relative to income, and second, we included expenditures on health insurance premiums in our total burden measure, providing a more accurate picture of health-related financial strain.
In this report, we compare the prevalence of high burdens among patients with cancer with other chronically ill and well patients. Next, we examine the variation in burdens among patients with cancer by insurance status and identify other sociodemographic characteristics associated with high burdens.
METHODS

Data
The data are from the Medical Expenditure Panel Survey-Household Component (MEPS-HC), sponsored by the Agency for Healthcare Research and Quality (Rockville, MD) . Every year, the MEPS panel is selected from among a sample of households that participated in the National Health Interview Survey (NHIS) in the previous year. MEPS is a 2-year rotating panel of households designed to yield nationally representative estimates of health care expenditures for the civilian, noninstitutionalized population. Data are collected through five rounds of interviews and include information on medical expenditures, insurance coverage and premiums, and other socioeconomic characteristics.
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Summarizing response rates for our sample was difficult, because there are eight panels and multiple rounds within each panel. Taking into account the NHIS response rate, 74.3% of MEPS-eligible households provided data for all of the first three rounds of 2001, computed as the product of round-specific response rates (81%, 95%, and 96% in rounds one, two, and three, respectively).
For the burden analysis among patients with cancer receiving treatment, we pooled 2001 to 2008 MEPS-HC data (2 years from panels six to 12 and 1 year from panel 13) to obtain a sample large enough to make reliable estimates for subgroups of patients with cancer. The unit of observation was a person 18 to 64 years of age. The pooled sample included 4,243 persons with cancer and 148,971 persons not receiving cancer treatment. Adults receiving treatment for cancer were those who reported any medical events associated with cancer during the calendar year.
For the after-tax burden analysis, we used the 2004 MEPS-HC, the most recent year for which simulated taxes are available. We simulated state and federal income taxes as well as Social Security and Medicare taxes. State and federal income taxes were simulated using the National Bureau of Economic Research TAXSIM model available at http://www.nber.org/ϳtaxsim/.
To examine burdens among cancer survivors who were not actively receiving treatment, we used the NHIS-MEPS linked sample. We could not use MEPS to identify cancer survivors from 2001 to 2007, because before 2007, survey participants were asked only about current conditions. However, cancer survivors are identified in the NHIS questionnaire for one randomly selected adult per household. The NHIS-MEPS linked sample for 2001 to 2008 includes 2,105 persons receiving cancer treatment, 2,005 cancer survivors not receiving cancer treatment, and 59,597 persons without cancer.
Measure of Out-of-Pocket Burdens
Our burden measure included out-of-pocket expenditures for all health care services, because health care burdens among those with cancer may be greater than the cost of cancer treatment. Health care burdens were defined at the family level as the share of family-level pretax income spent on healthrelated expenditures, because family members generally share financial resources. Families were defined as health insurance eligibility units (ie, persons related by blood, marriage, or adoption who would typically be eligible for coverage under a private family policy). Family-level burdens were then assigned to individuals within the family, and the results are presented at the person level, enabling us to quantify the number of persons at risk for high health care expenditure burdens.
In keeping with the literature, high burdens were defined as healthrelated spending in excess of 20% of income. [21] [22] [23] [24] [25] Although there is no consensus on what constitutes affordable costs, our results are robust when we use alternative thresholds such as 10% and 30%. Health care burden includes expenditures on all health care services. Total burden includes out-of-pocket expenditures on health insurance premiums in addition to out-of-pocket expenditures on health care services.
Two main methods used elsewhere in the literature are first, the population mean of the burden ratio, and second, the ratio of aggregate out-of-pocket expenditures to aggregate income.
26 Unlike these alternative measures, which are based on means, our approach identified those with the highest burdens, given the right-skewed distribution of expenditures.
Cancer and Other Medical Conditions
Our analysis is based on treated prevalence (ie, persons who reported medical treatment for cancer anytime during a year). Medical conditions were collected from households verbatim and coded by professional coders using the International Classification of Diseases, Ninth Revision (ICD-9). Condition categories were created using the AHRQ Clinical Classification Software (CCS), which compiles ICD-9 codes into clinically meaningful categories. 27 We classified persons into three mutually exclusive categories: cancer (ie, persons with one or more medical events [ambulatory visits, hospital, prescription medications, or other services] associated with CCS codes 11 to 45); other chronic condition (ie, persons with no medical events associated with cancer but with one or more medical events associated with other chronic conditions); and no chronic condition (ie, persons with no medical events associated with cancer or any other chronic condition). Chronic conditions were defined based on the fully specified ICD-9-CM diagnosis codes using the Healthcare Cost and Utilization Project Chronic Condition Indicator.
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Most skin cancers are not fatal, and some studies exclude skin cancers other than melanoma. However, because our focus was on financial burdens, our analysis includes all skin cancers. Our results when we excluded CCS code 23 (other nonepithelial skin cancer) were virtually identical.
Insurance Status
The nonelderly population, 18 to 64 years of age, was classified into four insurance categories: private group (employment-related) insurance, private nongroup (individual) insurance, public insurance, and no coverage. Persons with no private or public coverage anytime during the year were classified as having no coverage. Persons with multiple types of coverage during the year were assigned the coverage with the longest duration based on monthly insurance indicators. It is important to distinguish between the two types of private insurance, because nongroup insurance is generally more expensive and provides less generous benefits.
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Health Insurance Premiums
In MEPS, out-of-pocket premiums are collected from household respondents for private group and nongroup coverage. Although we focused on the nonelderly population, the burden measure includes health-related expenses for all family members. Therefore, we also simulated Medicare Part B premiums, taking into account that Medicaid pays Part B premiums for Medicare beneficiaries enrolled in Medicaid. Only 4.4% of nonelderly patients with cancer (190 of 4,243) lived in a household that included an elderly person. All premium amounts were prorated to account for the duration of coverage during the year.
Income
We constructed family-level income, adding income for all persons in the health insurance eligibility unit. We imposed a $100 floor for family income to deal with cases in which families had very low or negative incomes.
RESULTS
How do patients with cancer compare with other chronically ill and well patients in terms of out-of-pocket burdens?
Nonelderly adults with cancer were significantly more likely to have high out-of-pocket burdens compared with other chronically ill and well patients. We found that 13.4% of nonelderly adults with cancer had high total burdens, in contrast to 9.7% of those with other chronic conditions and 4.4% of those without chronic conditions (Fig 1) . Mean number of chronic conditions was significantly higher among patients with cancer compared with that among those with other chronic conditions (2.60 [SE, 0.04] v 2.15 [SE, 0.01]).
Although the prevalence of high burdens among patients with cancer and other chronically ill patients was similar among those age 18 to 39 years, among those age 40 to 54 and 55 to 64 years, patients with cancer were significantly more likely to have high burdens compared with those with other chronic conditions (Fig 1) Even when we controlled for insurance status, we found that those with cancer had higher burdens compared with those with other chronic conditions. The difference in prevalence of high burdens was largest among those with private nongroup insurance: with high burdens among 43.0% of adults with cancer versus 29.8% of other chronically ill and 16.4% of well patients (Fig 2) .
How do burdens vary among patients with cancer by sociodemographic characteristics? Table 1 presents out-of-pocket expenditures on health care and premiums, family income, and percentage with high health care and total burdens by sociodemographic characteristics. Among patients with cancer, those age 55 to 64 years, nonHispanic blacks, those who were never married or widowed, those with one child or no children, those who were not working, those who were poorer, those with lower education levels, those who lived in nonmetropolitan statistical areas, and those with other chronic conditions were more likely to have high out-of-pocket burdens.
How do burdens vary among patients with cancer by insurance status? Among nonelderly adult patients with cancer, 78% (n ϭ 4.5 million) had private group coverage, 5% (n ϭ 270,000) had private nongroup coverage, 11% (n ϭ 657,000) had public coverage, and 6% (n ϭ 376,000) were uninsured. Figure 3 shows the prevalence of high health care and high total burdens by insurance status among patients with cancer. Focusing on health care burdens, we see that the uninsured were most likely to have high burdens (25.7%). However, in terms of total burdens, those with private nongroup insurance were most likely to have high burdens (43.0%), followed by the uninsured (25.8%), those with public insurance (24.4%), and those with private group insurance (9.0%).
What services account for the largest share of out-of-pocket expenditures among patients with cancer? Among all nonelderly patients with cancer, prescription drugs and ambulatory care services each accounted for 36%, hospitalizations accounted for 10%, and other services accounted for 19% of out-of-pocket expenditures. Compared with those with private group insurance, those with private nongroup coverage had significantly higher expenditures for ambulatory care and other services, those with public insurance had significantly higher expenditures for prescription drugs but lower expenditures for ambulatory care and other services, and the uninsured had significantly higher expenditures for ambulatory care and hospitalizations (Fig 4) .
Extensions and Sensitivity Tests
How do burdens change when we use after-tax income and expenditures? Using after-tax income has two effects on burdens: first, health care expenses greater than 7.5% of adjusted gross income are tax deductible, lowering the after-tax burden of expenditures above the threshold, and second, after-tax income is significantly lower among the working age population, reducing the denominator of the burden measure. In our sample for 2004, mean pretax income was $79,908, whereas mean after-tax income was $62,026. Using the pretax method, 14.6% of patients with cancer had high burdens, whereas 16.5% had high burdens using the after-tax method. Thus, prevalence of high burdens among patients with cancer was 1.9 percentage points higher when using the after-tax method.
What is the prevalence of high burdens among cancer survivors who are not actively receiving treatment for cancer? First, we verified that the prevalence of high total burdens among patients with cancer receiving treatment in MEPS and in the NHIS-MEPS linked sample were consistent: 13.4% (SE, 0.7%) in MEPS and 13.3% (SE, 0.9%) in the NHIS-MEPS linked sample. Figure 5 shows that the prevalence of high total burdens was 11.5% (SE, 0.9%) among cancer survivors not actively receiving treatment for cancer, 13.3% (SE, 0.9%) among cancer survivors receiving treatment, and 6.7% (SE, 0.2%) among those without cancer. Thus, for the nonelderly population overall, the prevalence of high burdens was not significantly different among cancer survivors receiving and not receiving treatment for cancer. Controlling for insurance status, we found that among those with private group coverage, the prevalence of high burdens was higher among cancer survivors receiving treatment compared with those not receiving treatment. We found no difference in the prevalence of burdens between cancer survivors receiving and not receiving treatment among the uninsured and those with public coverage. We could not examine the variation among those with private nongroup coverage because of sample-size limitations.
DISCUSSION
We found that nonelderly adults with cancer were significantly more likely to have high out-of-pocket burdens compared with other chronically ill and well patients: 13.4% of nonelderly adults with cancer had high total burdens, in contrast to 9.7% of those with other chronic conditions and 4.4% of those without chronic conditions. Among patients with cancer, the following were associated with higher out-of-pocket burdens: private nongroup insurance, age 55 to 64 years, non-Hispanic black, never married or widowed, one child or no children, unemployed, lower income, lower education level, living in nonmetropolitan statistical areas, and having other chronic conditions. Furthermore, we found that even when not actively receiving treatment for cancer, expenditures among cancer survivors were higher than those among similar individuals without cancer. In the near future, for nonelderly adults with cancer, the temporary national high-risk pool and state-based health insurance exchanges are likely to lower out-of-pocket burdens, especially among the currently uninsured and those with nongroup private insurance. There are some limitations to our study. First, note that our goal was to examine the prevalence of high burdens among persons with cancer. It is beyond the scope of this study, nor did we attempt, to disentangle the multiple potential causal relationships between cancer and burdens, such as loss of employment and reduced income caused by illness. Second, our burden measure was based on income and did not capture any medical debt or depletion of savings because of cancer treatment. Third, we could not examine the variation in burdens by cancer site and treatment type because of sample-size limitations or by stage of illness, which is not reported in MEPS.
Despite these limitations, MEPS is an ideal source for analyzing out-of-pocket burdens, because it includes all payers and components of expenditures, unlike claims data, which only include covered services. The National Cancer Institute, American Cancer Society, National Center for Chronic Disease Prevention and Health Promotion of the Centers for Disease Control, and Office of Behavioral and Social Science Research of the National Institutes of Health are jointly funding a cancer supplement to MEPS for the panel starting in 2011. This cancer supplement will enable researchers to examine medical expenditures among patients with cancer in more detail.
In conclusion, high out-of-pocket burdens may affect treatment choice and deter patients from getting care. We believe that our findings on the prevalence and sociodemographics associated with high burdens will be helpful for patients with cancer. Furthermore, although a detailed patient-physician discussion of insurance status and costs may not be feasible, we believe that an awareness of out-ofpocket burdens is also useful for clinical oncologists.
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